{"id":62409,"date":"2025-12-26T13:05:50","date_gmt":"2025-12-26T12:05:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/glp-1-agonists-ozempic-wegovy-mounjaro-market-global-forecast-to-2033-growing-shift-of-weekly-injectables-toward-orals-and-multi-agonists-researchandmarkets-com\/"},"modified":"2025-12-26T13:05:50","modified_gmt":"2025-12-26T12:05:50","slug":"glp-1-agonists-ozempic-wegovy-mounjaro-market-global-forecast-to-2033-growing-shift-of-weekly-injectables-toward-orals-and-multi-agonists-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/glp-1-agonists-ozempic-wegovy-mounjaro-market-global-forecast-to-2033-growing-shift-of-weekly-injectables-toward-orals-and-multi-agonists-researchandmarkets-com\/","title":{"rendered":"GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market – Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2033”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0%<\/p>\n

\nThe report will help market leaders\/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.<\/p>\n

\nThe GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer’s disease, obstructive sleep apnea, and obesity.<\/p>\n

\nThe rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers.<\/p>\n

\nThe patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024.<\/strong><\/p>\n

\nBased on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter.<\/p>\n

\nPatented GLP-1 agonists dominate prescribing patterns due to their robust clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth.<\/p>\n

\nBy end user, the home-care settings and fitness\/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024.<\/strong><\/p>\n

\nBased on end user, the GLP-1 agonists market is segmented into home-care settings and fitness\/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness\/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management.<\/p>\n

\nHome care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment.<\/p>\n

\nThe US dominated the GLP-1 agonists market in 2024.<\/strong><\/p>\n

\nIn 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access.<\/p>\n

\nList of Companies Profiled in the Report:<\/strong><\/p>\n